Axsome Therapeutics (AXSM)

Executive Summary

Axsome Therapeutics is a commercial-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders. The company's approved product, Sunosi (solriamfetol), addresses excessive daytime sleepiness in narcolepsy and obstructive sleep apnea. Axsome's pipeline features several late-stage candidates, including AXS-05 (dextromethorphan/bupropion) for major depressive disorder and Alzheimer's disease agitation, and AXS-07 (meloxicam/rizatriptan) for migraine. Recent completion of pivotal phase 3 trials for AXS-05 in Alzheimer's agitation (ACCORD-2) and AXS-07 in migraine positions the company for near-term regulatory submissions. With a strong balance sheet and multiple potential catalysts, Axsome is well-positioned for significant value creation in the CNS space. Key upcoming events include FDA decisions and data readouts that could drive substantial upside.

Upcoming Catalysts (preview)

• Q2 2026FDA Approval Decision for AXS-05 in Alzheimer's Disease Agitation70% success
• Q3 2026NDA Submission for AXS-07 in Acute Migraine80% success
• Q4 2026Phase 3 Data Readout for Solriamfetol in Major Depressive Disorder50% success